{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:21:57Z","timestamp":1785352917479,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"suppl_6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"DOI":"10.1093\/cid\/civ819","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T11:47:40Z","timestamp":1447415260000},"page":"S678-S683","source":"Crossref","is-referenced-by-count":22,"title":["The Regulatory Pathway for Antifungal Drugs: A US Perspective"],"prefix":"10.1093","volume":"61","author":[{"given":"Joni","family":"Tillotson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"key":"key\n\t\t\t\t20171014032558_CIV819C1","article-title":"Securing new drugs for future generations: the pipeline for antibiotics"},{"key":"key\n\t\t\t\t20171014032558_CIV819C2","article-title":"Warning over hospital superbug linked to 16 deaths"},{"key":"key\n\t\t\t\t20171014032558_CIV819C3","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","article-title":"Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010\u20132011: application of new CLSI clinical breakpoints and epidemiological cut-off values for characterization of geographic and temporal trends in antifungal resistance","volume":"51","year":"2013","journal-title":"J Clin Microb"},{"key":"key\n\t\t\t\t20171014032558_CIV819C4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dku460","article-title":"Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance","volume":"70","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014032558_CIV819C5","article-title":"Non-albicans Candida infection: an emerging threat","year":"2014","journal-title":"Interdisc Persp Inf Dis"},{"key":"key\n\t\t\t\t20171014032558_CIV819C6","article-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20171014032558_CIV819C7","article-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"key\n\t\t\t\t20171014032558_CIV819C8","author":"Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20171014032558_CIV819C9","author":"Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20171014032558_CIV819C10","article-title":"National Strategy for combatting antibiotic resistant bacteria","author":"Presidential Council of Advisors on Science and Technology"},{"key":"key\n\t\t\t\t20171014032558_CIV819C11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1473-3099(12)70293-1","article-title":"A comprehensive regulatory framework to address the unmet need for new antibacterial treatments","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171014032558_CIV819C12","article-title":"1133 A phase III, randomized, double-blind trial to evaluate efficacy and safety of isavuconazole versus voriconazole in patients with invasive mold disease (SECURE): outcomes in hematopoietic stem cell transplant patients with invasive aspergillosis"},{"key":"key\n\t\t\t\t20171014032558_CIV819C13"},{"key":"key\n\t\t\t\t20171014032558_CIV819C14"},{"key":"key\n\t\t\t\t20171014032558_CIV819C15","article-title":"Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp. treated with isavuconazole: experience from the VITAL and SECURE Trials","year":"2014"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/61\/suppl_6\/S678\/20914086\/civ819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T07:26:03Z","timestamp":1507965963000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/61\/suppl_6\/S678\/437450\/The-Regulatory-Pathway-for-Antifungal-Drugs-A-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":15,"journal-issue":{"issue":"suppl_6","published-online":{"date-parts":[[2015,11,5]]},"published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/civ819","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,12,1]]},"published":{"date-parts":[[2015,11,5]]}}}